ACT PSM Abstract Presentations 2

Saturday, March 12, 2022

8:00 AM – 9:40 AM CST

Location:Coronado

Moderator(s)

Alex Kim, MD, PhD

Assistant Professor of Surgery
The Ohio State University Wexner Medical Center, The James Cancer Hospital and Solove Research Institute
Columbus, Ohio, United States
Ugwuji Maduekwe, MD, MMSc, MPH

Associate Professor of Surgery
Medical College of Wisconsin
Milwaukee, WI, United States

Participants should be aware of the following financial/non-financial relationships:

Alex C. Kim, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Ugwuji N. Maduekwe, MD, MMSc, MPH: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentations:

8:00 AM – 8:01 AM CST

Introductions
8:01 AM – 8:09 AM CST

A48: Pharmacokinetics of Nano-liposomal Irinotecan in a Phase 1 Study for Patients with Peritoneal Disease Treated with Heated Intraperitoneal Chemotherapy
Abstract Presenter: Megan M. Harper, MS, MD – University of Kentucky
8:09 AM – 8:11 AM CST

A48: Q&A
Abstract Presenter: Megan M. Harper, MS, MD – University of Kentucky
8:11 AM – 8:19 AM CST

A19: Circulating Tumor DNA Is Unreliable to Detect Somatic Gene Alterations in Gastrointestinal Peritoneal Carcinomatosis
Abstract Presenter: Brittany G. Sullivan, MD – University of California - Irvine General Surgery
8:19 AM – 8:21 AM CST

A19: Q&A
Abstract Presenter: Brittany G. Sullivan, MD – University of California - Irvine General Surgery
8:21 AM – 8:29 AM CST

A46: Harnessing the Immunogenic Effect of Heated Intraperitoneal Chemotherapy by Check Point Inhibitor to Treat Peritoneal Metastases from Colonic Origin in an Experimental Murine Model
Abstract Presenter: Eran Nizri, MD, PhD – Tel-Aviv Sourasky Medical Center
8:29 AM – 8:31 AM CST

A46: Q&A
Abstract Presenter: Eran Nizri, MD, PhD – Tel-Aviv Sourasky Medical Center
8:31 AM – 8:39 AM CST

A49: Phase I Trial of Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis
Abstract Presenter: Carlos HF Chan, MD, PhD – University of Iowa Hospitals and Clinics
8:39 AM – 8:41 AM CST

A49: Q&A
Abstract Presenter: Carlos HF Chan, MD, PhD – University of Iowa Hospitals and Clinics
8:41 AM – 8:49 AM CST

A24: Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Interim Analysis of Two Phase II Clinical Trials
Abstract Presenter: Benjamin L. Green, MD – NCI
8:49 AM – 8:51 AM CST

A24: Q&A
Abstract Presenter: Benjamin L. Green, MD – NCI
8:51 AM – 8:59 AM CST

A22: Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative
Abstract Presenter: Eliza W. Beal, MD, MS – The Ohio State University Wexner Medical Center/The James Cancer Hospital
8:59 AM – 9:01 AM CST

A22: Q&A
Abstract Presenter: Eliza W. Beal, MD, MS – The Ohio State University Wexner Medical Center/The James Cancer Hospital
9:01 AM – 9:09 AM CST

A37: Survival Outcomes of Optimally-treated Colorectal Metastases: The Importance of R0 Status in Hepatic and Peritoneal Surface Disease
Abstract Presenter: Ian Solsky, MD, MPH – Wake Forest
9:09 AM – 9:11 AM CST

A37: Q&A
Abstract Presenter: Ian Solsky, MD, MPH – Wake Forest
9:11 AM – 9:19 AM CST

A23: Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States
Abstract Presenter: Lucia M. Calthorpe, MPhil – University of California San Francisco
9:19 AM – 9:21 AM CST

A23: Q&A
Abstract Presenter: Lucia M. Calthorpe, MPhil – University of California San Francisco
9:21 AM – 9:31 AM CST

A25: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) in the Treatment of Peritoneal Carcinomatosis from Small Bowel Adenocarcinoma: A Systematic Review and Meta-analysis
Abstract Presenter: Deemantha G. Fernando, MD – Medical College of Wisconsin
9:31 AM – 9:40 AM CST

A25: Q&A
Abstract Presenter: Deemantha G. Fernando, MD – Medical College of Wisconsin